What is Exxua? Understanding a New Class of Antidepressant
•
2 min read
In September 2023, the U.S. Food and Drug Administration (FDA) approved Exxua (gepirone extended-release) for the treatment of major depressive disorder (MDD) in adults. This marked a significant milestone, introducing a novel class of oral antidepressants into the market that functions differently than many existing options like selective serotonin reuptake inhibitors (SSRIs).
